Inhibitors of D-amino acid oxidase
The present invention provides novel inhibitors of the enzyme D-amino acid oxidase. The compounds of the invention are useful for treating or preventing diseases and/or condition, wherein modulation of D-serine levels, and/or its oxidative products, is effective in ameliorating symptoms. The invention further provides methods of enhancing learning, memory and/or cognition. For example, the invention provides methods for treating or preventing loss of memory and/or cognition associated with neurodegenerative diseases, such as Alzheimer's disease. The invention further provides methods for preventing loss of neuronal function characteristic of neurodegenerative diseases. In addition, methods are provided for the treatment or prevention of neuropsychiatric diseases (e.g., schizophrenia) and for the treatment or prevention of pain and ataxia.
1. A compound having a structure according to Formula (Vc):
wherein
R 1a is a member selected from H, alkyl, and
where n is an integer from 0 to 3,
R 5a , R 5b and R 5c are members independently selected from H, C 1 to C 4 alkyl, C 1 to C 4 alkyne, nitrile, Br, Cl, F, OR 18a , furan, tetrahydrofuran, and pyrrole,
R 18a is a member selected from H and C 1 to C 4 alkyl,
R 6 is a member selected from OH and O − X + , wherein X + is a cation,
and any enantiomer, diastereoisomer, racemic mixture, enantiomerically enriched mixture, and enantiomerically pure form thereof.
2. A composition comprising a first stereoisomer and at least one additional stereoisomer of a compound according to claim 1 , wherein said first stereoisomer is present in an enantiomeric or diastereomeric excess of at least 90% relative to said at least one additional stereoisomer.
3. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
4. A compound having a structure according to Formula (IVc):
wherein
R 1a is a member selected from H, alkyl, and
where n is an integer from 0 to 3,
R 5a , R 5b and R 5c are members independently selected from H, C 1 to C 4 alkyl, C 1 to C 4 alkyne, nitrile, Br, Cl, F, OR 18a , furan, tetrahydrofuran, and pyrrole,
R 18a is a member selected from H and C 1 to C 4 alkyl,
R 6 is a member selected from OH and O − X + , wherein X + is a cation,
and any enantiomer, diastereoisomer, racemic mixture, enantiomerically enriched mixture, and enantiomerically pure form thereof.
5. A composition comprising a first stereoisomer and at least one additional stereoisomer of a compound according to claim 4 , wherein said first stereoisomer is present in an enantiomeric or diastereomeric excess of at least 90% relative to said at least one additional stereoisomer.
6. A pharmaceutical composition comprising a compound of claim 4 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
7. A compound having a structure according to Formula (VIIb):
wherein
R 30a and R 31a are members independently selected from H, C 1 to C 4 alkyl, and
where n is an integer from 0 to 3,
R 5a , R 5b and R 5c are members independently selected from H, C 1 to C 4 alkyl, C 1 to C 4 alkyne, nitrile, Br, Cl, F, and OR 18a ,
R 18a is a member selected from H and C 1 to C 4 alkyl,
R 6 is a member selected from OH and O − X + , wherein X + is a cation,
and any enantiomer, diastereoisomer, racemic mixture, enantiomerically enriched mixture, and enantiomerically pure form thereof.
8. A composition comprising a first stereoisomer and at least one additional stereoisomer of a compound according to claim 7 , wherein said first stereoisomer is present in an enantiomeric or diastereomeric excess of at least 90% relative to said at least one additional stereoisomer.
9. A pharmaceutical composition comprising a compound of claim 7 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
10. A compound having a structure according to Formula (VIIIb):
wherein
R 30a and R 31a are members independently selected from H, C 1 to C 4 alkyl, and
where n is an integer from 0 to 3,
R 5a , R 5b and R 5c are members independently selected from H, C 1 to C 4 alkyl, C 1 to C 4 alkyne, nitrile, Br, Cl, F, and OR 18a ,
R 18a is a member selected from H and C 1 to C 4 alkyl,
R 6 is a member selected from OH and O − X + , wherein X + is a cation,
and any enantiomer, diastereoisomer, racemic mixture, enantiomerically enriched mixture, and enantiomerically pure form thereof.
11. A composition comprising a first stereoisomer and at least one additional stereoisomer of a compound according to claim 10 , wherein said first stereoisomer is present in an enantiomeric or diastereomeric excess of at least 90% relative to said at least one additional stereoisomer.
12. A pharmaceutical composition comprising a compound of claim 10 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.